|
Dec 20
|
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
|
|
Dec 19
|
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
|
|
Dec 12
|
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
|
|
Oct 1
|
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable
|
|
Feb 1
|
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
|
|
Jan 6
|
Insider Sell: CFO Robert Andrade Sells 30,000 Shares of Fennec Pharmaceuticals Inc
|
|
Dec 6
|
With 31% stake, Fennec Pharmaceuticals Inc. (NASDAQ:FENC) seems to have captured hedge funds investors' interest
|
|
Dec 5
|
Fennec Announces Incremental $5 Million Investment from Petrichor
|
|
Oct 30
|
Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023
|
|
Sep 7
|
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
|